T78.41XS Arthus phenomenon, sequela

Name of the Condition

• Arthus phenomenon, sequela (ICD-10 Code: T78.41XS)

Summary

This code is used to document the sequela (late effect) of the Arthus phenomenon, a localized hypersensitivity reaction characterized by immune complex-mediated inflammation. It applies to residual effects following the acute phase of the condition, which typically occurs at the site of prior antigen exposure, such as after vaccination or injection of foreign proteins.

Causes

The Arthus phenomenon results from the deposition of antigen-antibody complexes in small blood vessels, triggering complement activation and inflammatory responses. Sequela may develop as a result of tissue damage or scarring from the initial reaction, persisting after the acute inflammatory phase has resolved.

Risk Factors

• Prior history of Arthus phenomenon
• Repeated antigen exposure
• High antigen concentration at the original exposure site
• Impaired immune regulation

Symptoms

• Persistent localized swelling or discoloration at the original exposure site
• Skin thickening or scarring
• Reduced range of motion (if near joints)
• Chronic pain or tenderness

Diagnosis

Diagnosis is based on clinical presentation and a history of prior Arthus phenomenon. Evaluation focuses on identifying residual tissue changes or functional limitations resulting from the initial reaction. Laboratory tests are typically not required for sequela documentation.

Treatment Options

• Symptomatic management of chronic pain or discomfort
• Physical therapy for mobility issues
• Topical treatments for skin changes (e.g., scar management)
• Monitoring for recurrent inflammation

Prognosis and Follow-Up

Prognosis depends on the extent of tissue damage from the initial reaction. Most sequela are stable but may require long-term monitoring. Follow-up is recommended to assess for recurrence or complications, especially if future antigen exposure is anticipated.

Complications

• Chronic skin changes (e.g., atrophy, hyperpigmentation)
• Functional impairment (e.g., limited movement)
• Psychological impact from visible scarring
• Risk of recurrent inflammation with re-exposure

Lifestyle & Prevention

• Avoid re-exposure to known triggering antigens
• Use proper injection techniques to minimize tissue damage
• Monitor for early signs of recurrence
• Maintain good skin care to support healing

When to Seek Professional Help

Seek care if new symptoms develop (e.g., increased swelling, pain, or redness) or if functional limitations worsen. Prompt evaluation is important to rule out recurrent inflammation or infection.

Tips for Medical Coders

Document the sequela clearly with a note linking it to the prior Arthus phenomenon. Ensure the code is used only when the condition is stable and the acute phase has resolved. Include details about the affected body part (if applicable) and any residual functional impact to support medical necessity.